These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1196 related items for PubMed ID: 17101300

  • 1. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [Abstract] [Full Text] [Related]

  • 2. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A.
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [Abstract] [Full Text] [Related]

  • 3. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 4. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 5. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S.
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [Abstract] [Full Text] [Related]

  • 6. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
    Musch E, Andus T, Malek M, Chrissafidou A, Schulz M.
    Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
    [Abstract] [Full Text] [Related]

  • 7. Curcumin for maintenance of remission in ulcerative colitis.
    Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD008424. PubMed ID: 23076948
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP.
    Am J Gastroenterol; 2009 Jun 17; 104(6):1452-9. PubMed ID: 19491859
    [Abstract] [Full Text] [Related]

  • 9. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
    Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M.
    Am J Gastroenterol; 2000 Jul 17; 95(7):1749-54. PubMed ID: 10925979
    [Abstract] [Full Text] [Related]

  • 10. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA.
    Am J Gastroenterol; 1999 Feb 17; 94(2):427-33. PubMed ID: 10022641
    [Abstract] [Full Text] [Related]

  • 11. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G.
    Am J Gastroenterol; 2004 Jun 17; 99(6):1122-8. PubMed ID: 15180735
    [Abstract] [Full Text] [Related]

  • 12. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R.
    Clin Gastroenterol Hepatol; 2003 Jan 17; 1(1):36-43. PubMed ID: 15017515
    [Abstract] [Full Text] [Related]

  • 13. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 17; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V, International Salofalk Foam Study Group.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1237-49. PubMed ID: 17944738
    [Abstract] [Full Text] [Related]

  • 15. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
    Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P, Deb R, Tiwari V, Rohatgi S, Dhingra R, Kedia S, Sharma PK, Makharia G, Ahuja V.
    J Crohns Colitis; 2014 Mar 01; 8(3):208-14. PubMed ID: 24011514
    [Abstract] [Full Text] [Related]

  • 16. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 01; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 17. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.
    Gastroenterology; 2009 Dec 01; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [Abstract] [Full Text] [Related]

  • 18. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S.
    Gastroenterology; 2010 Apr 01; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [Abstract] [Full Text] [Related]

  • 19. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR, Zakko S, Gordon GL, Murthy U, Sedghi S, Pruitt R, Merchant K, Bortey E, Forbes WP.
    Aliment Pharmacol Ther; 2012 Jul 01; 36(2):126-34. PubMed ID: 22617015
    [Abstract] [Full Text] [Related]

  • 20. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3106-14. PubMed ID: 19086960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.